- Home
- IMAB vs MIST Comparison
IMAB vs MIST Comparison
Compare IMAB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- MIST
- Stock Information
- Founded
- IMAB 2014
- MIST 2003
- Country
- IMAB United States
- MIST Canada
- Employees
- IMAB N/A
- MIST N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- MIST Health Care
- Exchange
- IMAB Nasdaq
- MIST Nasdaq
- Market Cap
- IMAB 83.8M
- MIST 81.5M
- IPO Year
- IMAB 2020
- MIST N/A
- Fundamental
- Price
- IMAB $1.06
- MIST $1.80
- Analyst Decision
- IMAB Strong Buy
- MIST Strong Buy
- Analyst Count
- IMAB 3
- MIST 3
- Target Price
- IMAB $8.00
- MIST $13.00
- AVG Volume (30 Days)
- IMAB 410.6K
- MIST 510.8K
- Earning Date
- IMAB 08-28-2024
- MIST 11-12-2024
- Dividend Yield
- IMAB N/A
- MIST N/A
- EPS Growth
- IMAB N/A
- MIST N/A
- EPS
- IMAB N/A
- MIST N/A
- Revenue
- IMAB $3,492,091.00
- MIST N/A
- Revenue This Year
- IMAB N/A
- MIST N/A
- Revenue Next Year
- IMAB N/A
- MIST N/A
- P/E Ratio
- IMAB N/A
- MIST N/A
- Revenue Growth
- IMAB N/A
- MIST N/A
- 52 Week Low
- IMAB $0.99
- MIST $1.12
- 52 Week High
- IMAB $2.54
- MIST $3.52
- Technical
- Relative Strength Index (RSI)
- IMAB 40.43
- MIST 68.42
- Support Level
- IMAB $1.02
- MIST $1.75
- Resistance Level
- IMAB $1.12
- MIST $2.09
- Average True Range (ATR)
- IMAB 0.08
- MIST 0.15
- MACD
- IMAB -0.01
- MIST 0.04
- Stochastic Oscillator
- IMAB 20.00
- MIST 62.86
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).